PHOSPHOTENSIN TUMOUR SUPPRESSOR GENE (PTEN) EXPRESSION PATTERNS IN ENDOMETRIAL HYPERPLASIAS AND ENDOMETRIOID CARCINOMA.

Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96.                       

Devi UK. Current status of gynecological cancer care in India. Journal of Gynecologic Oncology 2009;20(2):77-80.            

Creasman WT. Endometrial cancer: incidence, prognostic factors, diagnosis and treatment. Semin Oncol 1997;24(1 Suppl 1):S1-140, S1-50.

Kendall B, Ronnett B, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. The American Journal of Surgical Pathology 1998;22(8):1012-9.           

Mutter GL. Diagnosis of premalignant endometrial disease. Journal of Clinical Pathology 2002;55(5):326-31.             

Tantbirojn P, Triratanachat S, Trivijitsilp P, et al. Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. J Med Assoc Thai 2008;91(8):1161-5.             

Sarmadi S, Izadi-Mood N, Sotoudeh K, et al. Altered PTEN expression: a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagnostic Pathology 2009;4(1):41.            

Balasubramaniam G, Sushama S, Rasika B, et al. Hospital-based study of endometrial cancer survival in Mumbai, India. Asian Pacific Journal of Cancer Prevention 2013;14(2):977-80.                   

Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocrine Related Cancer 2003;10(2):203-8.              

Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57(21):4736-8.       

Akiyama-Abe A, Minaguchi T, Nakamura Y, et al. Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas. British Journal of Cancer 2013;109(6):1703-10.           

An HJ, Lee YH, Cho NH, et al. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 2002;41(5):437-45.             

Mutter GL, Ince TA, Baak JP, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61(11):4311-4.

Shanmugapriya M, Sudha M, Geetha P. A study of PTEN expression in endometrial hyperplasia and endometrioid type of endometrial carcinoma. Trop J Path Micro 2017;3(1):39-45.          

Kapucuoglu N, Aktepe F, Kaya H, et al. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax and apoptotic index. Pathology - Research and Practice 2007;203(3):153-62.                        

Orbo A, Kaino T, Arnes M, et al. Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. Gynecol Oncol 2004;95(1):82-8.            

Latta E, Chapman WB. PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 2002;14(1):59-65.